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Abstract
Attaining the full therapeutic utility of antisense and siRNA oligonucleotides will require
understanding of the biological barriers that stand between initial administration of these drugs and
their final actions within cells. This article examines some of the key barriers that affect the
biodistribution of oligonucleotides both in molecular form and when they are associated with
nanocarriers. An understanding of the biological processes underlying these barriers will aid in the
design of more effective delivery systems.
Introduction
There is currently enormous interest in the possibility of using oligonucleotides, including
siRNA, antisense, and aptamers, as therapeutic agents. Both antisense and nucleic acid
aptamers have reached clinical practice 1-3, while numerous clinical trials of siRNA are
underway 4. However, there is a widespread sense in the field that the full potential of
oligonucleotides as therapeutic agents will not be attained until better methodologies for
targeted delivery to cells and tissues are developed. Over the last few years many laboratories
have addressed this issue by chemical modification of oligonucleotides, via use of various
nanocarriers, or by some combination thereof. Our own approach has involved chemical
conjugation of oligonucleotides with receptor-specific targeting ligands 5, 6. However, many
other strategies have been devised and these have been the subject of multiple articles and
reviews, only a few of which can be cited here 7-12.
In this article we will take a different approach to the issue. We will seek to succinctly describe
some of the major biological barriers to efficient delivery of therapeutic oligonucleotides and
in some cases we will attempt to project means for overcoming these barriers. Hopefully this
discussion will be of some value to investigators already active in the field, but it may be of
more value to those who are considering entering the challenging area of nucleic acid
therapeutics. It is important to note that the barriers encountered by ‘monomeric’
oligonucleotides (that is single molecules of antisense, siRNA, or aptamers) will be quite
different from those encountered by oligonucleotides associated with various nanoparticles or
other nanocarriers. In both cases rapid clearance will be an issue, but the mechanisms and
locales involved will be very different, as discussed below. Since antisense oligonucleotides
predate siRNA, there is considerably more known about the pharmacokinetics and
biodistribution of the former than the later. However, information on how the body handles
various forms of siRNA is rapidly increasing.
Nuclease Stability
One of the first biological barriers encountered by administered siRNA and antisense
oligonucleotides is presented by the nuclease activity in plasma and tissues. The major activity
in plasma is a 3′ exonuclease, however, cleavage of internucleotide bonds can also take place.
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Chemical modification can drastically improve the stability of oligonucleotides in the
biological milieu, as well as allowing improvements in selectivity and reduced toxicity. There
have been several recent reviews that provide good overviews of chemical modification
strategies for siRNA 12, 13 and antisense 12, 14, 15. Below we will highlight a few key aspects.
Simple phosphodiester oligonucleotides are quite unstable. Substitution of sulfur for oxygen
forms phosphorothioate (PS) oligonucleotides, the most common stabilizing modification for
both antisense and siRNA. However, PS oligonucleotides tend to bind non-specifically to
proteins thus causing toxicities 16. Other highly improved oligonucleotide chemistries have
been developed including 2′-OH modifications, locked nucleic acids (LNAs), peptide nucleic
acids (PNAs), morpholino compounds, and hexitol nucleic acids (HNAs) 17, See Fig 1. In terms
of antisense use, oligonucleotides including these entities have high affinities for mRNA and
are more stable to nucleases; however, they do not support RNase H activity. Thus oligomers
with every residue modified cannot be used as typical antisense agents (although they may be
very effective for modification of splicing or translation arrest). The placement of several
central phosphorothioate residues, thereby creating ‘gapmers’, results in oligonucleotides that
activate RNase H while retaining many of the valuable properties of the parent compounds.
This is exemplified in a recent study using HNA modified antisense gapmers 18.
The nuclease stability and other properties of siRNA can also be enhanced by appropriate
chemical modifications. However, these have to be placed in the context of an overall design
strategy for the siRNA 19. A very common form of well-tolerated modification involves the
utilization of 2′-F or 2′-OMe residues 20-22. Another recent approach has involved use of LNA
modifications; in general limited LNA inclusion can improve stability and effectiveness,
whereas saturation of the oligonucleotide with LNA residues generally reduces efficacy 12,
23. Similarly, judicious placement of residues containing 6-carbon sugars instead of ribose can
result in siRNAs with improved stability and more persistent pharmacological actions 24, 25.
Thus the barrier presented by blood and tissue nucleases is rapidly being overcome by the
provision of a variety of chemically modified oligonucleotide building blocks. At this time
there does not seem to be one type of chemical modification that is superior in all situations.
It may be that different forms of oligonucleotides work best in different tissues, as has been
suggested by some recent studies 26.
Pharmacokinetics and Biodistribution
In this section we discuss the pharmacokinetic and biodistribution behavior of antisense and
siRNA oligonucleotides when administered as individual molecules. As we will see below,
the kidney plays a key role in oligonucleotide clearance in this case. The liver also plays an
important role, but that role is reinforced when the oligonucleotides are associated with
nanocarriers of various types, as discussed in another section.
Extensive studies of the pharmacokinetics and biodistribution of systemically administered
antisense oligonucleotides were undertaken in the 1990s and have been extensively reviewed
14, 27. Most of the early in vivo observations dealt with molecules having a phosphorothioate
backbone. Some important generalizations to emerge from these studies include the following.
(i) The biphasic plasma half-lives of oligonucleotides are in the range of minutes for t1/2α
(distributional phase) and many minutes to several hours for t1/2β (elimination phase). (ii)
Oligonucleotides are accumulated in most tissues, particularly the kidney and liver, but not the
central nervous system. (iii) Although phosphorothioate oligonucleotides are significantly
protein bound, the major route of elimination is via the kidneys. (iv) While the most detailed
studies have been done in rodents, in general, the pharmacokinetic behavior of
phosphorothioate oligonucleotides in humans is similar to that seen in lower animals.
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More recently there have been numerous studies of the pharmacokinetics and biodistribution
of various chemically modified antisense molecules. For example, a very comprehensive study
examined the fate of 2′-O-(2-methoxyethyl) (2′-MOE) modified antisense molecules in
rodents, monkeys and humans 28. This highly protein bound oligonucleotide had a longer
circulation lifetime than would be expected of a simple phosphodiester. However, at high doses
protein binding capacity was exceeded and more rapid renal excretion took place. Tissue uptake
was most extensive in liver and kidney, similar to older forms of antisense. Once again, the
behavior of the molecule in humans was predictable based on animal studies. Similarly, a study
using LNA (locked nucleic acid) modified antisense oligonucleotides in rodents found
extensive kidney uptake and excretion and a pharmacokinetic profile similar to standard
oligonucelotides 29.
The pharmacokinetics and biodistribution of siRNA has also received much recent attention.
Several studies in animals report that the biodistribution of siRNA duplexes is similar to that
of single stranded antisense molecules, with highest uptake in kidney followed by liver 30-32.
Interestingly, the high renal uptake has been associated with strong effects of the siRNA in
‘knocking down’ target molecules in that tissue 32. The technology for PK and biodistribution
studies of siRNA does not seem to be as sophisticated as that for antisense molecules. For
example, recent studies of siRNA biodistribution in animals have relied on radioactive tagging
31, or RNase protection assays 33, or simple HPLC 34, while some recent antisense studies have
used advanced capillary electrophoresis methods 35.
An interesting variation involves the use of cholesterol-conjugated oligonucleotides. This
approach was originated in the antisense literature 36 but has been extensively applied to
modifying the behavior of siRNA. Conjugation of cholesterol 33, tocopherol 37, or of other
lipid moieties 38, enhances binding of the oligonucleotide to serum lipoproteins and/or albumin.
This results in enhanced circulation lifetimes and, more importantly, in enhanced hepatic
uptake via the low-density lipoprotein receptor.
An important recent approach involves use of imaging technology to allow real time analysis
of oligonucleotide biodistribution and pharmacokinetics 30, 32, 39. Micro SPECT or other
radioimaging techniques can provide very detailed information on how an oligonucleotide is
distributed and cleared. However, like all methods that depend on radiolabeling, there is always
the underlying issue of separation of the label from the molecule being studied.
While it is clearly important to understand the pharmacokinetics and biodistribution of
antisense and siRNA oligonucleotides intended for therapeutic use, one should observe the
caution that this type of data may not be predictive of pharmacological effects. For example,
in a study of LNA antisense oligonucleotides designed to cause an alteration of mRNA splicing,
the major effects were observed in liver, colon, and small intestine; however the major site of
accumulation of the LNA was the kidney 26. Thus, there may be a disconnect between physical
biodistribution and functional biodistribution, with the latter determined not only by the amount
of oligonucleotide present in a tissue, but also by how effectively it interacts with the
biochemical machinery of the specific tissue.
Clearance via the Reticuloendothelial System / Role of the Liver and Spleen
In addition to circulating nucleases and renal clearance, a major barrier to effective in vivo
delivery of antisense drugs is clearance by the reticuloendothelial system (RES). The RES is
comprised of phagocytic cells, including circulating monocytes and tissue macrophages, whose
physiological function is to clear the body of foreign pathogens, remove cellular debris that is
generated during tissue remodeling, and to clear cells that have undergone apoptosis 40.
Phagocytic cells of the RES, particularly the abundant Kupffer cells in the liver and splenic
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macrophages, also detect and phagocytose antisense antisense and siRNA oligonucleotide, as
well as nanoparticle carriers 41 that may be used to enhance their delivery.
Macrophages differentiate from circulating monocytes, which migrate into tissue in the steady
state or in response to inflammation. During monocyte development, myeloid progenitor cells
sequentially give rise to monoblasts, pro-monocytes and finally monocytes, which exit the
bone marrow and enter the bloodstream. Monocytes migrate from the blood into tissue to
replenish specialized, tissue-specific macrophages 40.
Pathogens and particles in circulation are bound by opsonins, which include immnoglobulins,
complement components, and other serum proteins. Opsonized particles are recognized by a
variety of receptors present on the cell surface of macrophages. Immunoglobulin IgG-
opsonized particles are recognized by Fc receptors, activating a network of signaling pathways
that involve Src family kinases, PI3-kinase, phospholipase C, protein kinase C and Rho
GTPases. Fc receptor-mediated internalization is characterized by cytoskeletal rearrangement,
pseudopodia extension and engulfment of the opsonized particle 42.
Complement-opsonized particles are internalized by complement receptors. CR1 is a single-
chain transmembrane receptor, while CR3 and CR4 are members of the integrin family of
heterodimeric membrane proteins (CR3: αMβ2; CR4: αxβ2). CR1 is involved in particle binding
while CR3 and CR4 mediate internalization; all three require additional signals in order to
mediate internalization 42, 43. CRIg is a recently-identified complement receptor of the
immunoglobulin superfamily. Once an opsonized particle contacts the macrophage cell
surface, CRIg-expressing enosomes are recruited to the site of contact to replenish the plasma
membrane, where CRIg is thought to ensure improved binding of the particle to the macrophage
surface 43.
A third class of macrophage receptor is comprised of the scavenger receptors, which bind
diverse ligands such as LPS and modified lipoproteins. While they are involved in particle
binding, scavenger receptors require coreceptors to facilitate internalization. Importantly,
binding and uptake of monomolecular oligonucleotides by Kupffer cells in the liver 44, 45 and
proximal tubular cells in the kidney 46, 47 has been suggested to be mediated by scavenger
receptors; however, there have been some contrary reports 48.
Following particle internalization, the phagosome fuses with lysosomal compartments and its
contents are subject to enzymatic degradation by proteases and hydrolases that operate
efficiently in the low-pH lyosomal environment. Factors controlling the kinetics of phagosome-
lysosome fusion include the number and interaction of receptors in the phagosome and their
ligands on the particle surface, as well as a host of complex signaling pathways 42.
Tissues macrophages are most abundant in the liver (Kupffer cells) and spleen, tissues that also
receive high blood flow and exhibit fenestrated vasculature (see below). Thus it is not surprising
that these organs accumulate the highest concentrations of antisense and siRNA
oligonucleotides following systemic administration. Strategies to avoid uptake and clearance
by the RES following systemic administration include the use of nanoparticle carriers, targeting
ligands and conjugation of PEG 12, 49. In addition to its affect on biodistribution, uptake by
the RES has toxicological relevance, as in vivo toxicity often correlates with the capture and
long-term deposition of antisense drugs in RES organs, causing harmful side effect such as
renal tubule degeneration, splenomegaly and elevation of liver transaminases 50. Of note,
rodents are generally more sensitive to oligonucleotide-induced immune stimulation than
primates 51.
Clearly uptake by the RES plays a critical role in the biodistribution of oligonucleotides
associated with nanocarriers. However, as outlined above, uptake into RES-rich organs,
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particularly the liver, also plays a major role in the biodistribution of many types of
oligonucleotides in monomolecular form.
The Endothelial Barrier
The endothelial cells lining the vascular lumen present both a barrier and an opportunity for
oligonucleotide-based therapeutics. On the opportunity side they constitute a key cell type that
is readily accessed by systemically administered materials. Since endothelial cells play
essential roles in pathogenic processes as diverse as tumor angiogenesis, control of blood
pressure, and regulation of hemostasis, they offer a tempting therapeutic target. However, in
many cases nucleic acids need to pass across the endothelium and be delivered to tissue
parenchymal cells, and thus the endothelium becomes a major barrier. This is particularly true
when the oligonucleotides are part of a nanoparticle or other nanocarrier system, but it also
applies to some extent to ‘free’ oligonucleotides as well.
Endothelial cells line the vasculature, adhering tightly to the underlying extracellular matrix
largely via integrins, and forming junctions with each other via several types of cell-cell
adhesion molecules including VE-cadherin, JAM, occludins, claudins and PECAM. The
integrity of the endothelial junctions is influenced by complex signal transduction processes
52 that respond to a variety of mediators. For example, microvascular transport of
macromolecules increases during inflammation 53. In particular, there are a number of
mediators that increase vascular permeability including thrombin, histamine, VEGF, TNFα,
and reactive oxygen species 52. Therefore sites of inflammation are also potentially areas where
increased movement of oligonucleotides from blood to tissue may take place.
The permeation of both large and small molecules across normal endothelium is often described
in terms of a model that postulates abundant small pores of about 45 angstroms diameter
accompanied by relatively scarce large pores of about 250 angstroms 54. A significant
component of the small pore transport likely to take place via paracellular routes involving
imperfections in the junctions between the endothelial cells. Based on their molecular weights,
antisense and siRNA oligonucleotides should readily traverse the endothelial barrier via the
small pore system. However, it is important to keep in mind that the apparent hydrodynamic
radii of highly charged polynucleotides are larger than those of either globular proteins or
random coil uncharged polymers (eg dextrans) of similar molecular mass (Kang & Juliano,
unpublished observations). Thus the blood to tissue permeation rates may be slower than
expected based on molecular mass.
There is some controversy regarding the identity of the large pore system. Some endothelial
cells contain an abundance of small endosomal vesicles derived from calveolae, lipid rich
membrane structures containing the protein calveolin. One theory suggests that large pore
transport involves ‘transcytosis’, that is, entry of material into caveolae on the luminal side
followed by active, energy requiring movement of the calveolar vesicles across the cell, and
release on the abluminal side. However, other investigators suggest that the large pores
represent rare large defects in the endothelial junctions, or that multiple calveolar vesicles fuse
to form channels that cross the cell, in either case providing passive pathways for transport.
One argument for the vesicular model of large pore transport is that, while vascular
permeability declines dramatically with molecular size up to about 50 angstroms (the small
pore limit), it is only weakly dependent on molecular size above that. Unfortunately key
experiments testing energy dependence of large pore transport, or even the role of calveolin in
this process have provided contradictory results 55, 56.
In certain specialized tissues the organization of the endothelium permits the ready egress of
larger moieties. For example, the microvessels of both liver and spleen have relatively large
‘fenestrations’ of 100-200 nm diameter between endothelial cells 57. As mentioned above, the
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liver is one of the major sites of oligonucleotide accumulation, both as ‘free’ molecules and
when associated with liposomes or other nanoparticulate carriers.
Tumors are another instance where microvasculature abnormalities may potentially enhance
delivery of therapeutic oligonucleotides either as ‘free’ agents or when associated with
nanocarriers. Thus, the overall architecture of the vasculature differs between tumors and
adjacent normal tissue. In addition, there are often regional differences within the tumor and
between the primary tumor and its metastases. These differences include the number, length,
degree of branching of microvessels, and the velocity of blood flow 58. While small tumors
may be relatively homogeneous, larger ones usually have several distinct regions including:
(i) a necrotic, hypoxic core with almost no blood flow, (ii) a semi-necrotic region with relatively
poor flow in un-branched vessels, (iii) a stable region with branched vessels and relatively
good flow, (iv) and advancing front where active angiogenesis is taking place 58, 59. Transport
of macromolecules across the tumor endothelium involves diffusion, convection and possibly
transcytosis, with convective and active transport playing a greater role as molecular size
increases. The transvascular permeability of tumors is generally higher than that of normal
tissue, likely due to an increased number and size of the ‘large pore’ component 58. Some of
this is presumably associated with fenestrations between the endothelial cells that result from
rapid and disorganized angiogenesis in the tumor. Some studies have found pores or
fenestrations in tumor vessels ranging from 100 to over 700 nm 60; however, as always, tumors
display great heterogeneity in this regard.
A factor that works against the transvascular permeation of both molecules and nanocarriers
is the existence of a high interstitial fluid pressure in tumors. This obtunds the convective
component of transport, which relies on the differences in osmotic and hydrostatic pressure
between the blood and the interstitial fluid. The existence of a high interstitial pressure in
tumors has been ascribed to limited development of a lymphatic system in tumor tissue.
The relatively leaky character of the tumor endothelium, along with poor lymphatic drainage,
results in the so-called “EPR” effect (EPR, enhanced permeability and retention) that
sometimes allows selective accumulation of macromolecules or nanocarriers in tumors. The
larger pore size due to fenestrations of the endothelial lining of microvessels provides
opportunities for egress of relatively large entities, and the poor lymph flow means that the
extravasated material persists in the tumor longer than it would in normal tissue 60. Some
studies have suggested that it is the retention component due to limited lymphatic drainage that
is most important in the EPR effect 61. Therapeutic oligonucleotides associated with
nanocarriers such as lipoplexes, polymers, or various nanoparticles would be likely to
demonstrate some degree of EPR effect. By contrast, ‘free’ oligonucleotides may behave more
like small molecule drugs and not show a major EPR effect 29. However, free oligonucleotides
may offer some therapeutic advantages in cancer in cases where the tumor does not have a
grossly disturbed vascular architecture, or when, as is becoming common, anti-angiogenic
agents are being used as part of combination chemotherapy thus ‘normalizing’ the tumor
vasculature 62.
The fact that the endothelial lining in many tissues restricts egress of materials larger than 4
or 5 nanometers has implications for therapeutic use of oligonucleotides. It suggests that many
nanocarrier formulations will not be able to deliver to these sites in the body. Thus, while
nanoocarriers may be useful for delivery to certain types of tumors and to normal tissues having
fenestrated endothelia, other types of formulations may achieve broader tissue distribution. For
example, molecular conjugates of oligonucleotides with targeting ligands or with ‘cell
penetrating peptides’ may have advantages in terms of delivery to many types of tissues12.
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Cellular Uptake and Subcellular Distribution
Therapeutic oligonucleotides encounter their pharmacological targets within mammalian
cells63. To affect gene expression by RNaseH-mediated degradation of complementary
mRNA, or by splicing correction, antisense oligonucleotides need to enter the nucleus of cells.
In the cytoplasm, antisense oligonucleotides can function by translation arrest. Generally,
siRNA has to approach target mRNA that is associated with cytosolic RNA processing
machinery 64. However, RNAi was also observed to occur in the nucleus of mammalian cells
65. Evidence was further provided for a mechanism orchestrating the localization of the siRNA
in the cytoplasm or the nucleus, depending on where the target RNA resides 66.
Local exposure of oligonucleotides to their intracellular targets, and thereafter, the magnitude
and duration of pharmacologic response, is affected substantially by changes in cellular uptake
and subcellular distribution of oligonucleotides. Like other biological macromolecules that are
large, polar, and sometimes charged, oligonucleotides reach their pharmacological targets from
extracellular space by some form of endocytosis 63, which is subdivided into five major classes:
(i) the ‘classic’ clathrin-coated pit pathway; (ii) the caveolar pathway; (iii) one or more
noncaveolar, clathrin-independent pathways (CLIC pathways); (iv) phagocytosis (that mainly
takes place in ‘professional phagocytes’ such as macrophages and granulocytes); and (v)
macropinocytosis (in which macromolecules being internalized are simply dissolved in the
ambient medium) 67.
The first four classes often involve a cell surface receptor and are collectively termed receptor-
mediated endocytosis. It is these pathways that are mainly utilized in cellular delivery of
macromolecular drugs such as oligonucleotides. In general, receptor-mediated endocytosis
includes three major steps:
i. Receptor binding and internalization facilitate the initial entry of oligonucleotides into
the cell as the primary barrier for oligonucleotide transport. After the ligand binds to
the receptor, the ligand-receptor complex enters vesicles that bud from the cytosolic
face of the plasma membrane and then pinch off with the assistance of the dynamin
GTPase 68. Ligand-receptor binding determines which target cells and tissues
oligonucleotides are delivered to. In addition, the precise mechanism of entry can
affect the ultimate fate and function of the ligand-receptor complex. For example,
using the same initial clathrin-coated pit pathway, LDL-receptor binding ends up with
the degradation of LDL in lysosomes 69 whereas the transferrin-receptor complex
recycles the ligand to plasma membrane 70.
ii. Initial uptake is followed by sequential intracellular trafficking into a variety of low
pH endomembrane compartments, including early/sorting endosomes, late
endosomes/multi-vesicular bodies, and lysosomes. In some cases, receptors/ligands
can traffic to the Golgi complex. In many instances, receptor and ligand are
dissociated in the low pH endosome environment, and in some cases the receptor can
recycle back to the cell surface via the recycling endosomes. The complex flow of
endomembrane traffic is regulated by the Rab family of small GTPases and by
tethering complexes, while vesicular fusion events are controlled by SNARE proteins
71-73. The SNX (sorting nexin) proteins also are important in sorting and cargo
retrieval from endosomes 74. Vesicular trafficking can be rate-limiting in that many
nonproductive pathways can circumvent the transport of oligonucleotides to the
target, for example, sorting to secretory or lysosomal vesicles may lead to export of
oligonucleotides out of cells or degradation in the lysosomes.
iii. Ultimately, the oligonucleotide must exit from the endosome to reach its site of action
in the cytoplasm or nucleus. Endosomal trapping represents an important barrier for
oligonucleotide delivery; however, nuclear entry may not be the rate-limiting step for
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free oligonucleotides. Studies have shown that oligonucleotides are able to
continuously shuttle between the nucleus and the cytoplasm. A portion of the nuclear
uptake of oligonucleotides and their complexes is an active process mediated by
nuclear pore structures, however, it does not require classical nuclear localization
signals 75, 76. When oligonucleotides are bound to a nanocarrier, nuclear entry may
become rate-limiting due to the significant increase in size.
Efficient endocytosis requires functional synergy of cellular uptake, vesicular trafficking, and
endosomal release. These steps determine the magnitude and duration of oligonucleotide
exposure to its target, and ultimately govern pharmacological response. Depending on their
relative efficiency and capacity, cellular uptake, vesicular trafficking, or endosomal release
may control the cellular response of oligonucleotides when the corresponding transport step
becomes rate-limiting. In that case, identifying the rate-limiting step by mechanistic studies
can help design a specific strategy to overcome this barrier. For example, conjugating
oligonucleotides with endosomal release signal peptide 77 or nuclear localization signal peptide
linked to a nanocarrier 78 has been utilized to overcome the endosomal trapping or enhance
nuclear entry of oligonucleotides. On the other hand, the results of these peptide conjugations
also help understand the real barrier(s) in cellular delivery of oligonucleotides.
Although attention has been focused on the initial step of cellular uptake, studies have recently
emerged exploring intracellular trafficking and endosomal release of oligonucleotides into the
cytoplasm. Recently, a caveosomal trafficking pathway was proposed to deliver surprisingly
large amounts of naked siRNA to perinuclear sites in mammalian cells under stimulation of
single stranded phosphorothioate oligonulelotides 79, leading to measurable though moderate
target suppression 80. By attributing limited efficacy to intracellular sequestration of siRNA,
several strategies have been applied to improve the endosomal escape, including a
photochemical methodology 81 and peptide conjugation 77. In the latter study, conjugating an
endosomal release signal peptide from bacterial protein toxins did not enhance the cellular
uptake of siRNA, but nonetheless improved target inhibition dramatically 77, highlighting that
endosomal release is the rate-limiting step of intracellular delivery of naked siRNA to its site
of action in cytoplasm.
Similar lessons were learned from a study on intracellular delivery of oligonucleotides 5, in
which a bivalent RGD peptide was conjugated to an antisense oligonucleotide (termed 623)
that corrects splicing of a firefly luciferase gene mutant. The RGD-623 accumulated in cells
2-fold higher than free 623, however, it achieved a 7-fold higher effect on luciferase induction
5. The uptake and trafficking pathway involved an initial caveolar-mediated uptake followed
by trafficking to the trans-Golgi, indicating that the pharmacological effect of an antisense
oligonucleotide depends not only on total cell uptake but also on the intracellular trafficking.
These examples also provide evidence that DNA and RNA oligonucleotides are able to enter
the cells from the extracellular milieu without the need of a transfection agent, and certain cell
types may be equipped with pre-existing uptake and trafficking systems for that are favorable
for oligonucleotide effects. Elucidation of the cellular uptake, vesicular trafficking, and
endosomal release pathways of oligonucleotides can help optimize the chemistry of nucleic
acid drugs for greater biological effectiveness. Previous studies of oligonucleotide uptake have
extensively used several drugs as endocytotic pathway blockers. However, such inhibitors
often affect multiple uptake and trafficking pathways. Molecular inhibitors of endocytotic
pathways, such as dominant-negative Rab proteins to interfere selectively with trafficking
patterns 82, can provide additional mechanistic information.
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Multiple barriers still stand in the way of effective oligonucleotide therapeutics. Issues of
stability and efficacy have largely been overcome. However the matter of effective intracellular
delivery remains a key problem despite many clever attempts to surmount it. Overly rapid renal
clearance of monomolecular oligonucleotides remains an issue, as does unwanted RES
sequestration of siRNA or antisense nanoparticles. Steady progress is being made on all of
these aspects and hopefully oligonucleotide based therapeutics will soon become a valued part
of the pharmacological armamentarium.
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Chemical Modifications. The structures of various forms of chemically modified
oligonucleotide residues discussed in the text are illustrated.
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Oligonucleotide Pharmacokinetics. The normalized clearance rates of a chemically modified
antisense oligonucleotide are illustrated in several species including man. Adapted from
reference 28 with permission.
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The Endothelial Lining. An idealized version of the endothelial lining is illustrated with
indications of the large pore and small pore systems. Adapted with permission from reference
83.
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Intracellular Trafficking of Oligonucleotides. RGD-623-Tamra is a 2′-OMe-PS antisense
oligonucelotide that has a 5′-RGD targeting ligand and a 3′-Tamra fluorophore. Its distribution
in cells is compared to that of caveolin (A) or the avb3 integrin (B) (its receptor) as visualized
by immunostaining. Fletchings indicate areas of overlap. Adapted from reference 5 with
permission.
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